시장보고서
상품코드
1309355

세계의 이중특이성 항체 시장 규모, 점유율, 산업 동향 분석 보고서 : 적응증별, 지역별 전망 및 예측(2023-2030년)

Global Bispecific Antibodies Market Size, Share & Industry Trends Analysis Report By Indication (Cancer, Inflammatory & Autoimmune Disorder and Others), By Regional Outlook and Forecast, 2023 - 2030

발행일: | 리서치사: KBV Research | 페이지 정보: 영문 126 Pages | 배송안내 : 즉시배송


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

이중특이적 항체(BsAb, Bispecific Antibodies) 시장 규모는 2030년까지 802억 달러에 이를 것으로 예측되며, 예측기간 중 CAGR은 40.9%의 성장률로 상승할 전망입니다.

KBV 카디널 매트릭스에 제시된 분석에 따르면 Pfizer, Inc.는 이 시장의 주요 선구자입니다. 2022년 1월 Pfizer는 Dren Bio와 연구 제휴 및 라이선스 계약을 체결하고 Dren Bio의 독점적인 TARgeted Myeloid Engager and Phagocytosis Platform을 활용하여 종양 표적을 선택하기위한 치료 이중특이성 항체의 발견과 개발에 집중했습니다. Johnson & Johnson, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC 등 기업이 이 시장의 주요 혁신 기업입니다.

시장 성장 요인

집중 및 맞춤형 치료의 가능성 증가

개인화된 표적 치료제에 대한 수요 증가는 이 시장에 유리하게 작용할 것으로 예상됩니다. BsAb는 특정 세포 유형과 화학 물질을 특이적으로 표적화할 수 있기 때문에 부작용이 적고 보다 적은 효과적인 치료가 가능합니다. 기존의 의약품이 입수하기 어렵고, 효과도 기대할 수 없는 드문 질환에서는 이러한 주문제작의 접근이 특히 적합합니다. 따라서, 맞춤형 의료나 표적 의료에 사용되는 이중특이성 항체에 대한 수요 증가가 향후 수년간 시장 성장을 견인하게 될 것으로 보입니다.

연구개발 증가

명확한 생물학적 및 약리학적 특성을 가진 이중특이성 항체는 효과적인 치료제가 될 가능성을 가지고 있기 때문에 적극적인 연구의 대상이 되고 있습니다. 보다 강력하고 정확한 표적 약물 후보의 개발은 항체 공학 및 양성자 공학의 진보와 혁신에 의해 촉진될 것으로 예상됩니다. 최근에는 이러한 최첨단의 생물공학적 접근법을 적용함으로써 50가지 이상의 새로운 투약 형태를 만들 가능성이 나왔습니다. 최첨단 기술 창출과 신흥국 시장 확대를 위한 투자도 시장 성장에 기여하고 있습니다. 이러한 요소는 시장 확대에 유리한 기회를 가져올 것으로 보입니다.

시장 성장 억제 요인

부작용으로 인한 안전성 및 면역원성 우려

다른 치료제와 마찬가지로, 이중특이적 항체도 양호한 안전성 프로파일을 나타내야 합니다. 잠재적인 독성 및 면역원성(즉, 면역계의 항체에 대한 반응)에 대한 우려는 이중특이적 항체의 개발 및 수용에 영향을 미칠 수 있습니다. FDA는 2014년 재발 또는 내성화된 급성 림프아구성 백혈병(ALL)의 치료제로 브리나투모맙을 승인했습니다. 항체 기반 면역요법이 본질적으로 가지는 치명적일 수 있는 부정적인 영향과 그 놀라운 임상적 성공에 관한 새로운 지견이 탄생하고 있습니다. 따라서 이러한 요소는 시장 성장을 방해합니다.

적응증 전망

적응증에 따라 시장은 암, 염증성,자가 면역 질환 등으로 분류됩니다. 염증성 및 자가면역 질환 부문은 2022년 시장에서 상당한 성장률을 확보했습니다. 류마티스 관절염, 크론병, 건선, 다발성 경화증 등은 자가면역 질환과 염증성 질환으로 분류되는 질병의 일부입니다. 만성 염증, 조직 손상, 장기 기능 장애는 이러한 질병으로 인해 발생할 수 있으며 환자의 QOL에 큰 영향을 미칩니다. 이러한 질병을 가진 많은 환자는 현재 치료법에 잘 반응하지 않거나 견딜 수 없기 때문에 심각한 미충족 의료 요구를 초래합니다.

지역 전망

지역별로 볼 때 시장은 북미, 유럽, 아시아 태평양, 남미, 중동, 아프리카로 구분하여 분석할 수 있습니다. 북미 부문은 2022년 시장에서 가장 큰 수익 점유율을 획득했습니다. 이 지역 시장의 성장에 영향을 미치는 주요 변수는 여러 시장 진출 기업이 존재하고 그 기업이 다양한 개발을하고 있다는 것입니다. 그 결과, 연구개발비 증가, 기술 개발, 수요 증가가 가져왔습니다. 이중특이성 항체를 만들기 위한 보완적인 기술과 기술을 활용하기 위해 기업은 적극적으로 공동연구와 파트너십을 형성하고 있습니다. 이러한 공동 연구는 R&D 노력을 가속화하고 시장 성장에 기여합니다.

목차

제1장 시장 범위와 조사 방법

  • 시장의 정의
  • 목적
  • 시장 범위
  • 세분화
  • 조사 방법

제2장 시장 개요

  • 소개
    • 시장 개요
      • 시장의 구성과 시나리오
  • 시장에 영향을 미치는 주요 요인
    • 시장 성장 촉진 요인
    • 시장 성장 억제 요인

제3장 경쟁 분석-전 세계

  • KBV 카디널 매트릭스
  • 최근 산업 전체의 전략적 전개
    • 파트너십, 제휴, 계약
    • 임상시험과 승인
    • 인수와 합병
  • 주요 성공 전략
    • 주요 리딩 전략
    • 주요 전략적 동향

제4장 이중특이성 항체 시장 : 적응증별

  • 세계의 암 시장 : 지역별
  • 세계의 염증성·자가면역질환 시장 : 지역별
  • 세계의 기타 시장 : 지역별

제5장 이중특이성 항체 시장 : 지역별

  • 북미
    • 북미의 이중특이성 항체 시장 : 국가별
      • 미국
      • 캐나다
      • 멕시코
      • 기타 북미
  • 유럽
    • 유럽의 이중특이성 항체 시장 : 국가별
      • 독일
      • 영국
      • 프랑스
      • 러시아
      • 스페인
      • 이탈리아
      • 기타 유럽
  • 아시아 태평양
    • 아시아 태평양의 이중특이성 항체 시장 : 국가별
      • 중국
      • 일본
      • 인도
      • 한국
      • 싱가포르
      • 말레이시아
      • 기타 아시아 태평양
  • 남미·중동·아프리카
    • 남미·중동·아프리카의 이중특이성 항체 시장 : 국가별
      • 브라질
      • 아르헨티나
      • 아랍에미리트(UAE)
      • 사우디아라비아
      • 남아프리카
      • 나이지리아
      • 기타 지역

제6장 기업 개요

  • Amgen, Inc
  • F Hoffmann-La Roche Ltd.
  • Pfizer, Inc
  • Akeso, Inc
  • Johnson & Johnson(Janssen Global Services, LLC)
  • Taisho PhARmaceuticals Holding Co, Ltd.
  • Immunocore Holdings plc
  • GlaxoSmithKline PLC(GSK)
  • NovARtis AG
  • Allergan PLC(AbbVie, Inc)
LYJ 23.08.22

The Global Bispecific Antibodies Market size is expected to reach $80.2 billion by 2030, rising at a market growth of 40.9% CAGR during the forecast period.

A significant factor that will increase the market's growth rate is the increase in cancer incidence. Cancer segment is expected to generate more than 68% share of the market by 2030. The prevalence of sedentary lifestyle adoption suggests that many individuals are active, which increases their chance of developing cancer. The International Agency for Research on Cancer estimates that in Mexico, Argentina, and Saudi Arabia, there were, respectively, 195499, 130 878, and 27 885 new cases of cancer in 2020. The risk of cancer is further increased by a sedentary lifestyle that involves eating fast food and packaged goods. Therefore, growth in adopting a sedentary lifestyle reflects a rise in cancer rates, prompting the creation of more effective cancer medicines. Hence, the rising prevalence of these diseases and disorders is further expediting the expansion of the market.

The major strategies followed by the market participants are Partnerships as the key developmental strategy to keep pace with the changing demands of end users. For instance, In May, 2020, Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, signed an agreement with Lava Therapeutics B.V to discover and develop novel bispecific antibodies to gamma-delta T cells for the treatment of cancer. Additionally, In June, 2020, F. Hoffmann-La Roche Ltd. joined hands with Innovent Biologics, Inc. for the treatment of cancer, metabolic, autoimmune, and other major diseases. The collaboration aims at discovering, developing, and commercialization of bispecific antibodies and multiple cell therapies.

Based on the Analysis presented in the KBV Cardinal matrix; Pfizer, Inc. is the major forerunner in the Market. In January, 2022, Pfizer signed a research collaboration and license agreement with Dren Bio to concentrate on the discovery and development of therapeutic bispecific antibodies for selecting oncology targets utilizing Dren Bio's proprietary Targeted Myeloid Engager and Phagocytosis Platform. Companies such as Johnson & Johnson, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC are some of the key innovators in the Market.

Market Growth Factors

Rising possibilities for focused and customized therapy

The growing demand for individualized and targeted medicines is anticipated to be favorable for the market. BsAbs have the ability to be created to specifically target particular cell types or chemicals, enabling a more targeted, effective therapy with fewer adverse effects. In the context of uncommon diseases, when conventional medicines may not be accessible or effective, this tailored approach is especially pertinent. Therefore, the growing demand for bispecific antibodies to be used in personalized and targeted medicines will drive the growth of the market in the coming years.

Growing research & development endeavors

Bispecific antibodies with distinct biological and pharmacological properties are the subject of intense research because they have the potential to be effective therapeutic agents. The development of more potent and accurate target medication candidates is anticipated to be facilitated by advancements and innovation in antibody and proton engineering. The possibility to produce more than 50 new medication forms has recently been made possible by the application of these cutting-edge bioengineering approaches. Investments made to create cutting-edge technology and expand the number of developing marketplaces also contribute to the market's growth. These elements will present advantageous chances for the market to expand.

Market Restraining Factors

Safety and immunogenicity concerns owing to adverse side effects

Like any therapeutic agents, bispecific antibodies need to demonstrate a favorable safety profile. Concerns regarding potential toxicities and immunogenicity (i.e., the immune system's response to the antibodies) can impact the development and acceptance of bispecific antibodies. The FDA granted Blinatumomab approval in 2014 for treating acute lymphoblastic leukaemia (ALL) that has relapsed or become resistant. There is emerging knowledge of the intrinsic and potentially fatal negative consequences of antibody-based immunotherapies and their amazing clinical success. Therefore, these elements are obstructing the growth of the market.

Indication Outlook

Based on indication, the market is characterized into cancer, inflammatory & autoimmune disorder, and others. The inflammatory and autoimmune disorder segment procured a considerable growth rate in the market in 2022. Rheumatoid arthritis, Crohn's disease, psoriasis, and multiple sclerosis are just a few of the illnesses that fall under the category of autoimmune and inflammatory disorders. Chronic inflammation, tissue damage, and organ malfunction can result from these conditions, which can majorly impact a patient's quality of life. Many individuals with these illnesses don't respond well to or are intolerant of current treatments, leading to serious unmet medical requirements.

Regional Outlook

Region wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment acquired the largest revenue share in the market in 2022. Some of the primary variables influencing the regional market's growth are the existence of multiple market participants and the various developments undertaken by them. This has resulted in an increase in R&D spending, technological developments, and higher demand. In order to take advantage of complementary skills and technology to generate bispecific antibodies, businesses are also actively collaborating and forming partnerships. Such collaborations have sped up research and development efforts, contributing to the market's growth.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., F. Hoffmann-La Roche Ltd., Pfizer, Inc., Akeso, Inc., Johnson & Johnson (Janssen Global Services, LLC), Taisho Pharmaceuticals Holding Co., Ltd., Immunocore Holdings plc, GlaxoSmithKline PLC (GSK), Novartis AG, and Allergan PLC (AbbVie, Inc.).

Recent Strategies Deployed in Bispecific Antibodies Market

Partnerships, Collaboration and Agreements:

Dec-2022: Akeso Inc. teamed up with Summit Therapeutics Inc., a clinical-stage drug discovery and development company. Through this collaboration, the company aimed at developing and marketing its ivonescimab in the United States, Canada, Europe, and Japan.

Jun-2022: Immunocore Holdings Plc teamed up with Sanofi, a pharmaceutical and healthcare company. This hypothesis would be tested in Sanofi's clinical trial in patients with metastatic cutaneous melanoma (mCM), a population with significant unmet medical needs.

Jan-2022: Amgen teamed up with Amgen Generate Biomedicines, a therapeutics company. Under this collaboration, the companies aimed to develop and manufacture protein therapeutics to address 5 clinical ailments.

Jan-2022: Pfizer signed a research collaboration and license agreement with Dren Bio, a biopharmaceutical company, a developer of therapeutic antibodies for the treatment of cancer. This agreement aimed to concentrate on the discovery and development of therapeutic bispecific antibodies for selecting oncology targets utilizing Dren Bio's proprietary Targeted Myeloid Engager and Phagocytosis Platform.

Oct-2021: Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, entered into collaboration with Xencor, Inc., a clinical-stage biopharmaceutical company. The collaboration aimed for the development and commercialization of plamotamab and novel XmAb® B-cell addressing bispecific antibodies, designed to conditionally activate T cells through the CD28 co-stimulatory receptor.

Acquisitions and Merger:

Jul-2021: Amgen took over Teneobio, a clinical-stage biotechnology company. With this acquisition, the company aimed to leverage Teneobio's antibody platform to complement its prevailing capabilities. Moreover, the company also aimed to gain a diverse range of building blocks that can be created into new multispecific therapeutics.

Trials and Approvals:

Jun-2023: F. Hoffmann-La Roche Ltd. received FDA approval for its glofitamab, a new drug to be used in the treatment of diffuse large B-cell lymphoma (DLBCL) and large B-cell lymphoma (LBCL) arising from follicular lymphoma. The company announced that the drug would be marketed under the brand name Columvi.

Scope of the Study

Market Segments covered in the Report:

By Indication

  • Cancer
  • Inflammatory & Autoimmune Disorder
  • Others

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • Amgen, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer, Inc.
  • Akeso, Inc.
  • Johnson & Johnson (Janssen Global Services, LLC)
  • Taisho Pharmaceuticals Holding Co., Ltd.
  • Immunocore Holdings plc
  • GlaxoSmithKline PLC (GSK)
  • Novartis AG
  • Allergan PLC (AbbVie, Inc.)

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Global Bispecific Antibodies Market, by Indication
    • 1.4.2 Global Bispecific Antibodies Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market Composition and Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global

  • 3.1 KBV Cardinal Matrix
  • 3.2 Recent Industry Wide Strategic Developments
    • 3.2.1 Partnerships, Collaborations and Agreements
    • 3.2.2 Trials and Approvals
    • 3.2.3 Acquisition and Mergers
  • 3.3 Top Winning Strategies
    • 3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
    • 3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2020, Jun - 2022, Dec) Leading Players

Chapter 4. Global Bispecific Antibodies Market by Indication

  • 4.1 Global Cancer Market by Region
  • 4.2 Global Inflammatory & Autoimmune Disorder Market by Region
  • 4.3 Global Others Market by Region

Chapter 5. Global Bispecific Antibodies Market by Region

  • 5.1 North America Bispecific Antibodies Market
    • 5.1.1 North America Bispecific Antibodies Market by Indication
      • 5.1.1.1 North America Cancer Market by Country
      • 5.1.1.2 North America Inflammatory & Autoimmune Disorder Market by Country
      • 5.1.1.3 North America Others Market by Country
    • 5.1.2 North America Bispecific Antibodies Market by Country
      • 5.1.2.1 US Bispecific Antibodies Market
        • 5.1.2.1.1 US Bispecific Antibodies Market by Indication
      • 5.1.2.2 Canada Bispecific Antibodies Market
        • 5.1.2.2.1 Canada Bispecific Antibodies Market by Indication
      • 5.1.2.3 Mexico Bispecific Antibodies Market
        • 5.1.2.3.1 Mexico Bispecific Antibodies Market by Indication
      • 5.1.2.4 Rest of North America Bispecific Antibodies Market
        • 5.1.2.4.1 Rest of North America Bispecific Antibodies Market by Indication
  • 5.2 Europe Bispecific Antibodies Market
    • 5.2.1 Europe Bispecific Antibodies Market by Indication
      • 5.2.1.1 Europe Cancer Market by Country
      • 5.2.1.2 Europe Inflammatory & Autoimmune Disorder Market by Country
      • 5.2.1.3 Europe Others Market by Country
    • 5.2.2 Europe Bispecific Antibodies Market by Country
      • 5.2.2.1 Germany Bispecific Antibodies Market
        • 5.2.2.1.1 Germany Bispecific Antibodies Market by Indication
      • 5.2.2.2 UK Bispecific Antibodies Market
        • 5.2.2.2.1 UK Bispecific Antibodies Market by Indication
      • 5.2.2.3 France Bispecific Antibodies Market
        • 5.2.2.3.1 France Bispecific Antibodies Market by Indication
      • 5.2.2.4 Russia Bispecific Antibodies Market
        • 5.2.2.4.1 Russia Bispecific Antibodies Market by Indication
      • 5.2.2.5 Spain Bispecific Antibodies Market
        • 5.2.2.5.1 Spain Bispecific Antibodies Market by Indication
      • 5.2.2.6 Italy Bispecific Antibodies Market
        • 5.2.2.6.1 Italy Bispecific Antibodies Market by Indication
      • 5.2.2.7 Rest of Europe Bispecific Antibodies Market
        • 5.2.2.7.1 Rest of Europe Bispecific Antibodies Market by Indication
  • 5.3 Asia Pacific Bispecific Antibodies Market
    • 5.3.1 Asia Pacific Bispecific Antibodies Market by Indication
      • 5.3.1.1 Asia Pacific Cancer Market by Country
      • 5.3.1.2 Asia Pacific Inflammatory & Autoimmune Disorder Market by Country
      • 5.3.1.3 Asia Pacific Others Market by Country
    • 5.3.2 Asia Pacific Bispecific Antibodies Market by Country
      • 5.3.2.1 China Bispecific Antibodies Market
        • 5.3.2.1.1 China Bispecific Antibodies Market by Indication
      • 5.3.2.2 Japan Bispecific Antibodies Market
        • 5.3.2.2.1 Japan Bispecific Antibodies Market by Indication
      • 5.3.2.3 India Bispecific Antibodies Market
        • 5.3.2.3.1 India Bispecific Antibodies Market by Indication
      • 5.3.2.4 South Korea Bispecific Antibodies Market
        • 5.3.2.4.1 South Korea Bispecific Antibodies Market by Indication
      • 5.3.2.5 Singapore Bispecific Antibodies Market
        • 5.3.2.5.1 Singapore Bispecific Antibodies Market by Indication
      • 5.3.2.6 Malaysia Bispecific Antibodies Market
        • 5.3.2.6.1 Malaysia Bispecific Antibodies Market by Indication
      • 5.3.2.7 Rest of Asia Pacific Bispecific Antibodies Market
        • 5.3.2.7.1 Rest of Asia Pacific Bispecific Antibodies Market by Indication
  • 5.4 LAMEA Bispecific Antibodies Market
    • 5.4.1 LAMEA Bispecific Antibodies Market by Indication
      • 5.4.1.1 LAMEA Cancer Market by Country
      • 5.4.1.2 LAMEA Inflammatory & Autoimmune Disorder Market by Country
      • 5.4.1.3 LAMEA Others Market by Country
    • 5.4.2 LAMEA Bispecific Antibodies Market by Country
      • 5.4.2.1 Brazil Bispecific Antibodies Market
        • 5.4.2.1.1 Brazil Bispecific Antibodies Market by Indication
      • 5.4.2.2 Argentina Bispecific Antibodies Market
        • 5.4.2.2.1 Argentina Bispecific Antibodies Market by Indication
      • 5.4.2.3 UAE Bispecific Antibodies Market
        • 5.4.2.3.1 UAE Bispecific Antibodies Market by Indication
      • 5.4.2.4 Saudi Arabia Bispecific Antibodies Market
        • 5.4.2.4.1 Saudi Arabia Bispecific Antibodies Market by Indication
      • 5.4.2.5 South Africa Bispecific Antibodies Market
        • 5.4.2.5.1 South Africa Bispecific Antibodies Market by Indication
      • 5.4.2.6 Nigeria Bispecific Antibodies Market
        • 5.4.2.6.1 Nigeria Bispecific Antibodies Market by Indication
      • 5.4.2.7 Rest of LAMEA Bispecific Antibodies Market
        • 5.4.2.7.1 Rest of LAMEA Bispecific Antibodies Market by Indication

Chapter 6. Company Profiles

  • 6.1 Amgen, Inc.
    • 6.1.1 Company Overview
    • 6.1.2 Financial Analysis
    • 6.1.3 Regional Analysis
    • 6.1.4 Research & Development Expenses
    • 6.1.5 Recent strategies and developments:
      • 6.1.5.1 Partnerships, Collaborations, and Agreements:
      • 6.1.5.2 Acquisition and Mergers:
  • 6.2 F. Hoffmann-La Roche Ltd.
    • 6.2.1 Company Overview
    • 6.2.2 Financial Analysis
    • 6.2.3 Segmental and Regional Analysis
    • 6.2.4 Research & Development Expense
    • 6.2.5 Recent strategies and developments:
      • 6.2.5.1 Partnerships, Collaborations, and Agreements:
      • 6.2.5.2 Trials and Approvals:
  • 6.3 Pfizer, Inc.
    • 6.3.1 Company Overview
    • 6.3.2 Financial Analysis
    • 6.3.3 Regional & Segmental Analysis
    • 6.3.4 Research & Development Expense
    • 6.3.5 Recent strategies and developments:
      • 6.3.5.1 Partnerships, Collaborations, and Agreements:
  • 6.4 Akeso, Inc.
    • 6.4.1 Company Overview
    • 6.4.2 Financial Analysis
    • 6.4.3 Regional Analysis
    • 6.4.4 Research & Development Expenses
    • 6.4.5 Recent strategies and developments:
      • 6.4.5.1 Partnerships, Collaborations, and Agreements:
  • 6.5 Johnson & Johnson (Janssen Global Services, LLC)
    • 6.5.1 Company Overview
    • 6.5.2 Financial Analysis
    • 6.5.3 Segmental &Regional Analysis
    • 6.5.4 Research & Development Expenses
    • 6.5.5 Recent strategies and developments:
      • 6.5.5.1 Partnerships, Collaborations, and Agreements:
      • 6.5.5.2 Acquisition and Mergers:
  • 6.6 Taisho Pharmaceuticals Holding Co., Ltd.
    • 6.6.1 Company Overview
    • 6.6.2 Financial Analysis
    • 6.6.3 Segmental and Regional Analysis
    • 6.6.4 Research & Development Expenses
  • 6.7 Immunocore Holdings plc
    • 6.7.1 Company Overview
    • 6.7.2 Financial Analysis
    • 6.7.3 Research & Development Expenses
    • 6.7.4 Recent strategies and developments:
      • 6.7.4.1 Partnerships, Collaborations, and Agreements:
  • 6.8 GlaxoSmithKline PLC (GSK)
    • 6.8.1 Company Overview
    • 6.8.2 Financial Analysis
    • 6.8.3 Regional Analysis
    • 6.8.4 Research & Development Expense
  • 6.9 Novartis AG
    • 6.9.1 Company Overview
    • 6.9.2 Financial Analysis
    • 6.9.3 Segmental and Regional Analysis
    • 6.9.4 Research & Development Expense
  • 6.10. Allergan PLC (AbbVie, Inc.)
    • 6.10.1 Company Overview
    • 6.10.2 Financial Analysis
    • 6.10.3 Regional Analysis
    • 6.10.4 Research & Development Expense
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제